Catalent invests over $27 million to commercialize Zydis Ultra

7 Mar 2019

Zydis Ultra allows a patented and innovative drug coating to be introduced during a product’s formulation, enabling the dosage of active ingredient to be up to four times higher than a conventional Zydis ODT.

Catalent Pharma Solution is to invest more than $27 million to commercialize its next-generation oral disintegrating tablet (ODT) technology, Zydis Ultra. The technology allows an increased drug load and taste masking to be incorporated into the company’s Zydis ODT dosage form, which is a unique freeze-dried tablet that disperses almost instantly in the mouth without water.

Catalent invests over $27 million to commercialize Zydis Ultra

Zydis Ultra allows a patented and innovative drug coating to be introduced during a product’s formulation, enabling the dosage of active ingredient to be up to four times higher than a conventional Zydis ODT, while maintaining its speed of dispersion and superior mouth feel. To date, more than 36 products have been launched using Zydis technology in more than 60 countries. The novel coating technology significantly expands the range of drug candidates that can be formulated using the Zydis ODT platform, including analgesics, anti-allergy treatments and anti-infectives.

Zydis is recognized as one of the world’s best performing ODTs, and has well-established advantages over conventional oral dosage forms, including improved patient compliance, adherence and convenience, particularly within certain patient populations such as geriatrics, pediatrics and patients suffering from disorders of the central nervous system.

“Our team of scientists has been working on the next generation of ODT formulations for several years, to leverage the advantages that the dose form brings to patients in terms of convenience and increased drug compliance,” said Jonathan Arnold, President, Oral Drug Delivery at Catalent. “We have been collaborating with several partners on specific products utilizing the Zydis Ultra technology, and this investment coincides with these development programs reaching proof of concept and full development stages.”

Catalent’s 250,000 sq. ft. site in Swindon, UK houses the company’s Zydis fast dissolving tablet development and manufacturing operation, which produces over one billion ODTs annually and employs more than 600 people.

Read More

Related news

Funding to accelerate delivery of Univercells' vaccine portfolio

Funding to accelerate delivery of Univercells' vaccine portfolio

11 Oct 2019

European financing to support Univercells’ R&D investments to develop four essential and undersupplied global health vaccines to be produced at affordable prices, high quality and large volumes.

Read more 
Industrial-scale manufacture of therapeutic exosomes

Industrial-scale manufacture of therapeutic exosomes

10 Oct 2019

Coordinated purification process development service accelerates progress to clinical trials, and scale-up manufacturing.

Read more 
Janssen opens new biomanufacturing building in Ireland

Janssen opens new biomanufacturing building in Ireland

8 Oct 2019

Expansion creates 200 new full-time jobs and increases the company’s production capacity by an additional 19,100 m2.

Read more 
BASF and Biomillenia join forces in microbiome research to promote healthy skin

BASF and Biomillenia join forces in microbiome research to promote healthy skin

7 Oct 2019

Research aims to identify novel dermocosmetic active ingredients via unique microbiome-on-a-chip technology.

Read more 
Allergan expands Refresh eye treatment portfolio

Allergan expands Refresh eye treatment portfolio

7 Oct 2019

A trifecta of relief formulated with HydroCell technology offers new artificial tear options for patients suffering from eye dryness.

Read more 
BASF strengthens biotechnology footprint to enter natural F&F ingredients market

BASF strengthens biotechnology footprint to enter natural F&F ingredients market

3 Oct 2019

Market entrance with biotech-based natural vanillin, valencene and nootkatone.

Read more 
Unidose device approved for Tosymra sumatriptan spray

Unidose device approved for Tosymra sumatriptan spray

3 Oct 2019

Provides migraine sufferers with a convenient, patient-friendly delivery approach.

Read more 
One-stop-platform for plant-based nutraceuticals

One-stop-platform for plant-based nutraceuticals

2 Oct 2019

In 2020, nutra brands will look to ensure they have plant-based options across all product classes with many actively looking to move entire portfolios plant-based.

Read more 
BASF's new bioactive ingredient the wellness elixir for healthy skin

BASF's new bioactive ingredient the wellness elixir for healthy skin

1 Oct 2019

The active ingredient is a 100% natural extract from the chaga mushroom, obtained using an innovative eco-friendly technology: subcritical water extraction.

Read more 
Arctoris secures funding to advance novel robotic drug discovery platform

Arctoris secures funding to advance novel robotic drug discovery platform

1 Oct 2019

Platform will enable scientists and biotechnology entrepreneurs worldwide to make discoveries faster and more efficiently,

Read more